Can abruptly stopping atenolol prescribed for postural orthostatic tachycardia syndrome cause my recent electrocardiogram findings of sinus rhythm at 83 bpm with borderline QTc and anterior T‑wave inversion?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Abrupt Atenolol Withdrawal and ECG Changes in POTS

Yes, abruptly stopping atenolol can contribute to your ECG findings, though the sinus rhythm at 83 bpm with borderline QTc and anterior T-wave inversion likely represents a combination of withdrawal effects and your underlying POTS physiology rather than a dangerous rebound phenomenon.

Understanding Beta-Blocker Withdrawal in Your Context

The FDA label for atenolol explicitly warns that "patients with coronary artery disease, who are being treated with atenolol, should be advised against abrupt discontinuation of therapy" and notes that "severe exacerbation of angina and the occurrence of myocardial infarction and ventricular arrhythmias have been reported" 1. However, this warning primarily applies to patients with coronary artery disease, not POTS patients.

What the Evidence Shows About Atenolol Withdrawal

  • Atenolol has a more benign withdrawal profile than other beta-blockers: Research specifically examining abrupt atenolol withdrawal in patients with severe stable angina found no serious coronary events during 144 hours post-withdrawal, with only gradual increases in heart rate and minor clinical consequences 2.

  • The withdrawal timeline is gradual, not abrupt: When atenolol was stopped after long-term therapy (19 months average), blood pressure and heart rate returned to baseline gradually over a period that "greatly exceeded the time for elimination of atenolol," with no evidence of rebound hypertension or increased cardiac adrenergic sensitivity 3.

  • Your heart rate of 83 bpm is actually reasonable: In POTS patients, atenolol works by blunting the excessive sympathetic response 4. Your current heart rate suggests partial return of your baseline POTS physiology rather than dangerous rebound tachycardia.

Interpreting Your Specific ECG Findings

The Sinus Rhythm at 83 bpm

  • This represents your underlying POTS returning: POTS is characterized by excessive heart rate increases (≥30 bpm or >120 bpm) upon standing, not necessarily elevated resting heart rates 5, 6.

  • 83 bpm at rest is not concerning: This is within normal range and far from the tachycardia that would indicate a dangerous withdrawal syndrome 2.

The Borderline QTc

  • Atenolol withdrawal does not typically cause QT prolongation: The research on atenolol withdrawal focused on heart rate and blood pressure changes, not QT interval effects 2, 3.

  • This finding warrants attention but is not an emergency: Borderline QTc can occur in POTS patients independent of medication changes and should be monitored, but does not represent acute withdrawal danger 5.

The Anterior T-Wave Inversions

  • T-wave changes can reflect autonomic dysfunction in POTS: The excessive sympathetic activity characteristic of POTS can produce ECG changes including T-wave abnormalities 5, 6.

  • These are not specific markers of atenolol withdrawal: The studies examining atenolol cessation did not report T-wave inversions as withdrawal phenomena 2, 3.

Critical Distinction: You Don't Have Coronary Disease

The FDA warning about atenolol withdrawal applies primarily to patients with coronary artery disease, not POTS patients 1. The mechanism of concern—unmasking of underlying ischemia—is not relevant to your condition unless you have concurrent coronary disease.

What You Should Do Now

Immediate Actions

  • Monitor your orthostatic symptoms: Track your heart rate response when standing (measure supine, then after 2,5, and 10 minutes of standing) to assess if your POTS symptoms are returning 5.

  • Watch for concerning symptoms: Seek immediate care if you develop chest pain, syncope, sustained palpitations, or heart rates consistently >120 bpm at rest 1.

  • Hydration and salt loading: Increase fluid intake to 2-3 liters daily and salt intake to 10-12 grams daily to counteract the hypovolemia component of POTS 5, 6.

Follow-Up Considerations

  • The ECG changes need evaluation but are not emergent: Your anterior T-wave inversions and borderline QTc should be assessed in context of your clinical presentation, but do not represent acute danger from withdrawal 7.

  • Consider gradual atenolol taper if restarting: If symptoms become intolerable, the FDA recommends that "when discontinuation of atenolol is planned, the patients should be carefully observed and advised to limit physical activity to a minimum" 1.

Common Pitfalls to Avoid

  • Don't assume all beta-blocker withdrawal is the same: The dangerous "beta-blocker withdrawal syndrome" has occurred "almost exclusively in patients taking propranolol, many of whom had unstable angina at the time of withdrawal," not with atenolol in stable patients 2.

  • Don't restart atenolol without addressing why it was stopped: If the hospital discontinued it for a specific reason (hypotension, bradycardia, etc.), that issue needs resolution first 1.

  • Don't ignore the possibility of concurrent cardiac pathology: While your symptoms likely reflect POTS physiology, the anterior T-wave inversions warrant evaluation to exclude structural heart disease 7.

Timeline Expectations

Based on the pharmacology of atenolol withdrawal, you can expect:

  • Days 1-5: Gradual increase in resting heart rate and return of orthostatic symptoms 2, 3.

  • Days 5-10: Peak return of baseline POTS physiology, with maximal orthostatic tachycardia 2.

  • Beyond 2 weeks: Stabilization at your pre-treatment baseline, assuming no other interventions 3.

Your ECG findings at 83 bpm suggest you are in the early-to-mid withdrawal phase, experiencing return of your underlying POTS rather than a dangerous rebound phenomenon.

Related Questions

Is Flonase (fluticasone propionate) safe in patients with Postural Orthostatic Tachycardia Syndrome (POTS)?
In a patient with chronic postural orthostatic tachycardia syndrome who is off beta‑blockers, currently tachycardic (~121 bpm) with lactic acidosis, a QT interval of 440 ms and a Bazett‑corrected QTc of 624 ms, how should the QTc be interpreted and what management steps are recommended for the prolonged QT interval?
What could be causing my constant sinus tachycardia, excessive sweating, and worsening orthostatic hypotension with convulsive syncope on top of my Postural Orthostatic Tachycardia Syndrome (POTS) diagnosis?
I have postural orthostatic tachycardia syndrome (POTS) and chest pain; how can I tell if it’s just POTS‑related discomfort or an emergency indicating a T‑wave abnormality or myocardial ischemia?
I have postural orthostatic tachycardia syndrome and recently stopped atenolol; my ECG now shows sinus tachycardia at 102 bpm, PR interval 156 ms, QRS duration 81 ms, and corrected QT interval 490 ms. What is causing the tachycardia and QT prolongation and how should I manage it?
What are the clinical manifestations of Behçet's disease?
Can a 10‑mm mass located next to the right renal artery decrease the glomerular filtration rate (GFR)?
In a 38-year-old man with chronic anabolic‑steroid use, currently taking methylphenidate 10 mg daily for ADHD, and experiencing generalized anxiety, can sertraline be started, and what dosing and monitoring plan is appropriate?
What is the most appropriate next step in management for a patient with symptomatic primary hyperparathyroidism (fatigue, recurrent ureteric stones, bone pain, serum calcium 3.5 mmol/L) and a 2‑cm parathyroid adenoma?
How should acute bronchiolitis be managed in infants and children under two years, including supportive care, oxygen therapy, hydration, use of bronchodilators, systemic steroids, antibiotics, admission criteria, ribavirin for high‑risk infants, and palivizumab prophylaxis?
What is the relationship between mast cell activation syndrome (MCAS) and heart‑rate variability (HRV), and how should it be evaluated and managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.